Partnership with GHU Paris Psychiatry & Neurosciences GHU Paris and AiiNTENSE agree on a partnership for the development of tools for textual data structuring and semantic enrichment of health data warehouses. This partnership has given rise to the "NeuroMonitor" project. AiiNTENSE is developing a digital platform called "NeuroMonitor" to help Read more...
Industrial and academic research is mobilising for cybersecurity in health. AiiNTENSE is taking the lead in securing predictive tools in neuroscience by participating in the creation of Cybaile In the field of health, cybersecurity is at the heart of the challenges posed by artificial intelligence (AI), which is being driven by the European Union's Read more...
The "augmented resuscitator" platform awarded at the Silicon Awards 2022 Talan and AiiNTENSE are proud to have won the bronze medal of the Silicon Awards 2022 in the "Innovation" category for the "augmented resuscitator" platform. A solution that enables better patient care Read more...
Epimed Solutions and AiiNTENSE announce a strategic partnership for the distribution in France of Epimed Solutions' solutions used for quality management and efficiency support in intensive care units. Epimed Solutions and AiiNTENSE are pleased to announce a strategic partnership to integrate Epimed's tools Read more...
Talan and AiiNTENSE announce a strategic partnership to develop decision support solutions for intensive care units Talan and AiiNTENSE are pleased to announce a strategic partnership to accelerate the development of technology solutions for medical decision support for intensive care patients. Read more...
Memory loss, depression... The neuropsychological after-effects of Covid-19 (article in L'Express de Valentin Ehkirch of 09/08/2020) Psychologists and neurologists are working to understand where the psychological and cognitive after-effects of Covid-19 patients come from. It is the concern that comes, those of the after-effects left by the Covid-19... Read more...
NeuroCOVID: a neurology tele-expertise platform for the management of patients contaminated with COVID-19.
Two of the foundersAiiNTENSE, Prof. SHARSHAR and Dr. MAZERAUD, launch a therapeutic trial, ICAR, to determine whether treatment with intravenous immunoglobulin (IVIG) - compared to placebo - significantly reduces mortality and the duration of mechanical ventilation in patients with ARDS.
AiiNTENSE receives at the CES in Las Vegas the Deloitte "Coup de Coeur" award of the Prix Innovation Bercy / ITM in the health category Contact us
AiiNTENSE is one of the 10 startups selected as part of the ITM/Bercy Innovation Award to participate in January 2020 at CES Las Vegas, a global innovation event.